AVT48 (canakinumab biosimilar)
Immunology
Early PhaseIn Development
Key Facts
About Alvotech
Alvotech is a purpose-driven biosimilar company with a mission to improve lives by expanding global access to affordable biologic medicines. The company leverages a fully integrated platform from cell line development to commercial manufacturing to achieve speed and control. Its strategic pipeline includes several approved biosimilars, such as AVT02 (adalimumab), and a deep portfolio targeting major immunology and oncology drugs. Alvotech is publicly traded and partners with commercialization experts to bring its products to market worldwide.
View full company profileTherapeutic Areas
Other Immunology Drugs
| Drug | Company | Phase |
|---|---|---|
| AVT02 (adalimumab biosimilar) | Alvotech | Approved |
| AVT04 (ustekinumab biosimilar) | Alvotech | Approved |
| AVT05 (golimumab biosimilar) | Alvotech | Approved |
| AVT16 (vedolizumab biosimilar) | Alvotech | Early Phase |
| AVT10 (certolizumab pegol biosimilar) | Alvotech | Early Phase |
| AVT28 (ixekizumab biosimilar) | Alvotech | Early Phase |
| AVT41 (guselkumab biosimilar) | Alvotech | Early Phase |
| AVT65 (ofatumumab biosimilar) | Alvotech | Early Phase |
| AVT19 (dupilumab biosimilar) | Alvotech | Early Phase |